Role of Trained Immunity in the pathogenesis and treatment of Still’s disease

Concept

Aim of this study is to determine the role of  Trained Immunity in the pathogenesis of Still’s disease, and the therapeutic potential of inhibiting this mechanism for the treatment of this condition. Several factors are ideally aligned to achieve these ambitious research goals: a large cohort of patients with Still’s disease, an optimal experimental platform, and a synergistic enterprise with world-leading experts in the field.

Facts and Figures

Project Lead
G Cavalli
IRCCS San Raffaele Hospital
cavalli.giulio@hsr.it
FOREUM research grant: €200.000
2020 - 2023

Meet the Team

G Cavalli
IRCCS San Raffaele Hospital
M Netea
Radboud University
A Ravelli
Ospedale Pediatrico Giannina Gaslini

Objectives

In order to test the hypotheses the following aims are proposed:
• AIM 1: to determine epigenetic and immunometabolic features of TI in SD monocytes.
• AIM 2: to determine the therapeutic potential of inhibiting TI for the treatment of SD.

 

Patient Voice

This study is important to many patients with AOSD and SJIA, and many already volunteered to donate samples. In collaboration with AMRI (a non-profit patient organisation with investment in SD) there is a strong engagement of patients in the research process.

Regular updates on research findings, instructions on research strategies based on patients’ insight, and development for shared initiatives for effective dissemination of findings to societal stakeholders will be provided.

Goals/Milestones

1, Month 12: identification of functional and epigenetic features of TI in SD monocytes.
2, Month 24: identification of immunometabolic features of TI in SD monocytes.
3, Month 30: evaluation of TI as a predictor of clinical outcomes in SD.
4, Month 36: Identification of strategies effectively inhibiting TI for the treatment of SD.